Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Olutasidenib is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1; IC50s = 0.021 and 0.114 µM for IDH1R132H and IDH1R132C, respectively).1 It is selective for mutant IDH1 over wild-type IDH1 and mutant IDH2 (IC50s = 22.4, 27.3, and >100 μM for wild-type IDH1, IDH2R172K, and IDH2R140Q, respectively). Olutasidenib inhibits production of ɑ-hydroxyglutaric acid (2-HG; Item Nos. 25894 | 16374) in U87 cells expressing mutant IDH1R132H, IDH1R132C, IDH1R132L, IDH1R132G, and IDH1R132S with IC50 values of 0.009, 0.039, 0.042, 0.006, and 0.009 µM, respectively. It reduces intratumor 2-HG levels in HCT116-IDH1R132H and HCT116-IDH1R132C mouse xenograft models when administered at doses of 12.5, 25, and 50 mg/kg.
WARNING This product is not for human or veterinary use.
1. Structure-